Stress-induced activation of the dynorphin/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference

Journal of Neuroscience

Volumn 32, Issue 4, 2012, Pages 1488-1495

  Smith, Jeffrey S ^a   Schindler, Abigail G ^a   Martinelli, Emma ^a   Gustin, Richard M ^a   Bruchas, Michael R ^a   Chavkin, Charles ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3, 4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL) CYCLOHEXYL] BENZENEACETAMIDE; DYNORPHIN; KAPPA OPIATE RECEPTOR; NICOTINE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; FORCED SWIMMING TEST; IMMUNOHISTOCHEMISTRY; MALE; MAZE TEST; MOUSE; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; STEREOTACTIC PROCEDURE; STRESS; THALAMUS POSTERIOR NUCLEUS;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; AMYGDALA; ANIMALS; CONDITIONING, OPERANT; DYNORPHINS; MALE; MICE; MICE, INBRED C57BL; NICOTINE; RECEPTORS, OPIOID, KAPPA; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84863028984     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2980-11.2012     Document Type: Article

References (67)

1. Balerio GN, Aso E, Maldonado R (2005) Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacol 181:260-269.
2. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS (1993) Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264:489-495.
3. Benowitz NL (2008) Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 83:531-541.
4. Berrendero F, Kieffer BL, Maldonado R (2002) Attenuation of nicotineinduced antinociception, rewarding effects, and dependence in κ-opioid receptor knock-out mice. J Neurosci 22:10935-10940.
5. Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R (2010) Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev 35:220-231.
6. Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP (1994) Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. J Pharmacol Exp Ther 271:353-361.
7. Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S, Chavkin C (2007) Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282:29803-29811.
8. Bruchas MR, Land BB, Lemos JC, Chavkin C (2009) CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS 4:e8528.
9. Bruchas MR, Land BB, Chavkin C (2010) The dynorphin-kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Research 1314:44-55.
10. Buczek Y, Lê AD, Wang A, Stewart J, Shaham Y (1999) Stress reinstates nicotine seeking but not sucrose solution seeking in rats. Psychopharmacol (Berl) 144:183-188.
11. Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440-447.
12. Castellano C, Libri V, Ammassari-Teule M (1988) The amygdala mediates the impairing effect of the selective kappa-opioid receptor agonist U-50,488 on memory in CD1 mice. Behav Brain Res 30:259-263.
13. Changeux JP (2010) Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 11:389-401.
14. Chavkin C, James IF, Goldstein A (1982) Dynorphin is a specific endogenous ligand of the κ-opioid receptor. Science 215:413-415.
15. Corrigall WA, Herling S, Coen KM (1988) Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacol 96:29-35.
16. Costall B, Elizabeth MK, Naylor RJ, Onaivi E (1989) The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 33:97-203.
17. Daughton DM, Roberts D, Patil KD, Rennard SI (1990) Smoking cessation in the workplace: evaluation of relapse factors. Prev Med 19:227-230.
18. Davenport KE, Houdi AA, Van Loon GR (1990) Nicotine protects against mu opioid receptor antagonism by β-funaltrexamine: evidence for nicotine induced release of endogenous opioids in brain. Neurosci Lett 113:40-46.
19. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M (1995) Preproenkephalin mRNA and methionine encephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem 64:1878-1883.
20. Erb S, Stewart J (1999) A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stressinduced reinstatement of cocaine seeking. J Neurosci 19:RC35.
21. File SE, Kenny PJ, Ouagazzal A (1998) Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behav Neurosci 112:1423-1429.
22. Galeote L, Berrendero F, Bura SA, Zimmer A, Maldonado R (2009) Prodynorphin gene disruption increases the sensitivity to nicotine selfadministration in mice. Int J Neuropsychopharmacol 12:615-625.
23. Gilbert DG, Meliska CJ, Williams CL, Jensen RA (1992) Subjective correlates of cigarette-smoking-induced elevations of peripheral betaendorphin and cortisol. Psychopharmacol 106:275-281.
24. Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M, Nagase H, Suzuki T (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404-413.
25. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH (1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A 95:15049-15054.
26. Hogg S (1996) A review of the validity and variability of the elevated plusmaze as an animal model of anxiety. Pharmacol Biochem Behav 54:21-30.
27. Horan P, Taylor J, Yamamura HI, Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tailflick test. J Pharmacol Exp Ther 260:1237-1243.
28. Ismayilova N, Shoaib M (2010) Alteration of intravenous nicotine selfadministration by opioid receptor agonist and antagonists in rats. Psychopharmacol 210:211-220.
29. Isola R, Duchemin AM, Tejwani GA, Neff NH, Hadjiconstantinou M (2000) Glutamate receptors participate in the nicotine induced changes of metenkephalin in striatum. Brain Res 878:72-78.
30. Isola R, Zhang H, Tejwani GA, Neff NH, Hadjiconstantinou M (2009) Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology 201:507-516.
31. Jackson KJ, Carroll FI, Negus SS, Damaj MI (2010) Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacol 210:285-294.
32. Jenison RL, Rangel A, Oya H, Kawasaki H, Howard MA (2011) Value encoding in single neurons in human amygdala during decision making. J Neurosci 31:331-338.
33. Jones JL, Day JJ, Aragona BJ, Wheeler RA, Wightman RM, Carelli RM (2010) Basolateral amygdala modulates terminal dopamine release in the nucleus accumbens and conditioned responding. Biol Psychiatry 67:737-744.
34. Kalman D (2002) The subjective effects of nicotine: methodological issues, a review of experimental studies, and recommendations for future research. Nicotine Tob Res 4:25-70.
35. Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA Jr (2011) Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 70:425-433.
36. Koob GF (2009) Brain stress systems in the amygdala and addiction. Brain Res 1293:61-75.
37. Kota D, Martin BR, Robinson SE, Damaj MI (2007) Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther 322:399-407.
38. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008) The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28:407-414.
39. Lê AD, Quan B, Juzystch W, Fletcher PJ, Joharchi N, Shaham Y (1998) Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. Psychopharmacol 135:169-174.
40. LeDoux J (2003) The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 23:727-738.
41. Leri F, Flores J, Rodaros D, Stewart J (2002) Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci 22:5713-5718.
42. Liu X, Jernigan C (2011) Activation of the opioidμ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug selfadministration. Prog Neuropsychopharmacol Biol Psychiatry 35:146-153.
43. Marco EM, Llorente R, Pérez-Alvarez L, Moreno E, Guaza C, Viveros MP (2005) The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behav Brain Res 163:212-218.
44. Marlatt GA, Gordon JR (1985) Relapse prevention: maintenance strategies in the treatment of addictive behavior. New York: Guilford.
45. Marty MA, Erwin VG, Cornell K, Zgombick JM (1985) Effects of nicotine on beta-endorphin, alpha MSH, andACTHsecretion by isolated perfused mouse brains and pituitary glands, in vitro. Pharmacol Biochem Behav 22:317-325.
46. McKennell AC (1970) Smoking motivation factors. Br J Soc Clin Psychol 9:8-22.
47. McLaughlin JP, Marton-Popovici M, Chavkin C (2003) Kappa opioid antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23:5674-5683.
48. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C (2006) Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacol 31:787-794.
49. Melief EJ, Miyatake M, Bruchas MR, Chavkin C (2010) Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A 107:11608-11613.
50. Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM (2011) κ-Opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacol 61:35-42.
51. Peters MF, Zacco A, Gordon J, Maciag CM, Litwin LC, Thompson C, Schroeder P, Sygowski LA, Piser TM, Brugel TA (2011) Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 103:27-34.
52. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776.
53. Picciotto MR (2003) Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 24:493-499.
54. Ramos A (2008) Animal models of anxiety: do I need multiple tests? Trends Pharmacol Sci 29:493-496.
55. Ribeiro SC, Kennedy SE, Smith YR, Stohler CS, Zubieta JK (2005) Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors 29:1264-1280.
56. Schindler AG, Li S, Chavkin C (2010) Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/ kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanisms. Neuropsychopharmacol 35:1932-1942.
57. Shaham Y, Stewart J (1995) Stress reinstates heroin-seeking in drug-free animals: an effect mimicking heroin, not withdrawal. Psychopharmacology 119:334-341.
58. Shaham Y, Erb S, Stewart J (2000) Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev 33:13-33.
59. Shippenberg TS, LeFevour A, Heidbreder C (1996) κ-Opioid receptor agonists prevent sensitization conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 1996 2:545-554.
60. Shippenberg TS, Zapata A, Chefer VI (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116:306-321.
61. Smith AP, Lee NM (1988) Pharmacology of dynorphin. Annu Rev Pharmacol Toxicol 28:123-140.
62. Stuber GD, Sparta DR, Stamatakis AM, van Leeuwen WA, Hardjoprajitno JE, Cho S, Tye KM, Kempadoo KA, Zhang F, Deisseroth K, Bonci A (2011) Excitatory transmission from the amygdala to nucleus accumbens facilitates reward seeking. Nature 475:377-380.
63. Tye KM, Stuber GD, de Ridder B, Bonci A, Janak PH (2008) Rapid strengthening of thalamo-amygdala synapses mediates cue-reward learning. Nature 453:1253-1257.
64. Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, Thompson KR, Gradinaru V, Ramakrishnan C, Deisseroth K (2011) Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 471:358-362.
65. Walker BM, Zorrilla EP, Koob GF (2011) Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict Biol 16:116-119.
66. Wittmann W, Eduard SE, Rosskothen I, Gaburro S, Singewald N, Herzog H, Schwarzer C (2009) Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacol 34:775-785.
67. Zhu H, Lee M, Agatsuma S, Hiroi N (2007) Pleiotropic impact of constitutive fosB inactivation on nicotine-induced behavioral alterations and stress-related traits in mice. Hum Mol Genet 16:820-836.